<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Oncology on FinanClub</title>
    <link>https://finan.club/tags/oncology/</link>
    <description>Recent content in Oncology on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 06 Aug 2023 11:33:53 +0000</lastBuildDate><atom:link href="https://finan.club/tags/oncology/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>0968 GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Sun, 06 Aug 2023 11:33:53 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:968
Chances: Gilead Sciences expects a third of sales to come from its cancer treatments by 2030, which could drive future growth. Gilead Sciences has a rich portfolio of therapies for life-threatening infectious diseases, including pulmonary and cardiovascular diseases and cancer. The company&amp;rsquo;s CEO mentioned that Gilead is overperforming significantly, excluding one-time items, indicating positive performance.</description>
    </item>
    
  </channel>
</rss>
